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Abstract
Background: Activating mutations in the KRAS gene occur frequently in human tumors, including colorectal 
carcinomas; most mutations occur in codons 12 and 13. Mutations in KRAS have been associated with poor response to 
anti-epidermal growth factor receptor antibodies. Therefore, an accurate and readily available analysis of KRAS 
mutational status is needed. The aim of this study was to evaluate concordance between KRAS assays performed by 6 
different laboratories.
Methods: Forty formalin-fixed paraffin-embedded colorectal cancer tumor samples were obtained. Sample sections 
were submitted for KRAS mutation analysis to 5 independent commercial laboratories (Agencourt, Gentris, Genzyme, 
HistoGeneX, and Invitek) and to the Amgen DNA Sequencing Laboratory for direct polymerase chain reaction 
sequencing. The assay used by Invitek is no longer commercially available and has been replaced by an alternative 
technique. Results from the commercial services were compared with those from Amgen direct sequencing by κ 
statistics.
Results: KRAS mutations were observed in codon 12 and/or 13 in 20 of 40 (50%) samples in Amgen direct sequencing 
assays. Results from HistoGeneX (κ = 0.95), Genzyme (κ = 0.94), and Agencourt (κ = 0.94) were in almost perfect 
agreement with these results, and the results from Gentris were in substantial agreement with the results from Amgen 
(κ = 0.75). The Invitek allele-specific assay demonstrated slight agreement (κ = 0.13).
Conclusions: This study provides data on the comparability of KRAS mutational analyses. The results suggest that most 
(but not all) commercial services provide analysis that is accurate and comparable with direct sequencing.
Background
Inhibitors of epidermal growth factor receptor (EGFR),
including the monoclonal antibodies panitumumab and
cetuximab, have recently emerged as treatment options
for metastatic colorectal cancer (mCRC) [1,2]. Mutations
in  KRAS have been associated with poor responses to
both cetuximab and panitumumab in patients with CRC
[3]. The aim of this study was to evaluate comparability
among KRAS assays performed by 6 different laboratories
in order to identify a vendor and assay that would be used
to determine the clinical utility of KRAS in our pivotal
panitumumab trial in mCRC [4].
Methods
Tissue Samples and DNA Isolation
Formalin-fixed paraffin-embedded (FFPE) human CRC
samples (N = 40) were obtained from the following pro-
curement service providers: Asterand plc (Detroit, MI),
Ardais Corp (Lexington, MA), and the National Disease
Research Interchange (Philadelphia, PA). Fourteen (35%)
samples were from men, 20 (50%) were from women, and
6 (15%) were unassigned (Table 1). The median age was
67 years (range, 35-94 y); age data were not available for 7
patients. The samples were primary resections from
colon adenocarcinoma (n = 36), rectum adenocarcinoma
(n = 3), and rectum carcinoma (n = 1) with a range of
poorly to well-differentiated tumors of different stages
with variable tumor, normal, stromal, and necrotic con-
tent. The aim was to select samples that were representa-
tive of samples expected in clinical trials. All study
procedures were conducted in accordance with the Dec-
laration of Helsinki.
Mutational analysis of KRAS sequences was performed
by the Amgen DNA Sequencing Laboratory and 5 inde-
pendent laboratories that provide diagnostic services for
academic/clinical research laboratories and/or clinical
trials. Each laboratory was provided with 10-μm tissue
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sections from all 40 samples in 2007 except Agencourt.
Agencourt was provided with extracted genomic DNA
from the remaining 35 specimens in 2009. DNA was
extracted using the QIAamp FFPE Tissue kit (Qiagen Inc,
Carlsbad, CA) according to the manufacturer's instruc-
tions, with the addition of a 16-hour proteinase K lysis
step.
Direct Sequencing of KRAS by the Amgen DNA Sequencing 
Laboratory
Exon 2 of KRAS was amplified from isolated genomic
DNA using the Roche Expand Long Template PCR Sys-
tem (Roche Applied Science, Indianapolis, IN). The for-
ward primer sequence was 5'-AAGGTACTGGTGGAG
TATTTG-3', and the reverse was 5'-GTACTCAT-
GAAAATGGTCAGAG-3', resulting in a predicted ampl-
icon length of 295 bp. Cycling conditions were as follows:
93°C, 3 minutes; 40-46 cycles at 93°C, 15 seconds; 62°C,
30 seconds; 72°C, 30 seconds; and 72°C, 4 minutes. Poly-
merase chain reaction (PCR) products were directly
sequenced in triplicate (3730xl DNA Analyzers; Applied
Biosystems). Sequences were analyzed using Sequencher®
software (Gene Codes Corporation, Ann Arbor, MI).
Results were reported when all 3 parallel PCR products
generated 4 acceptable sequences, resulting in a total of
12 sequences for each sample.
Commercial KRAS Mutation Analysis
Five commercial services were contracted to analyze
KRAS  mutational status. HistoGeneX (Antwerp, Bel-
gium) used the DxS K-RAS Mutation Test Kit (DxS Ltd,
Manchester, UK) that interrogates the 7 most common
somatic mutations of codons 12 and 13 (G12A, G12D,
G12R, G12V, G12C, G12S, and G13D) using allele-spe-
cific PCR amplification with an amplification-refractory
mutation system technology in combination with Scor-
pion®  detection to measure amplification products by
real-time PCR [5,6]. The DxS K-RAS Mutation Test Kit is
capable of detecting approximately 1% of mutated KRAS
from background wild-type DNA.
Gentris Clinical Genetics, Inc. (Morrisville, NC, USA)
assessed KRAS mutational status by direct DNA sequenc-
ing of codons 12 and 13. Gentris used a pathology service
(Integrated Laboratory Systems, Inc.) to enrich for tumor
tissue by removing normal tissue from the slides and then
extracting genomic DNA from the remaining material.
Isolated genomic DNA was then amplified with primers
that spanned codons 12 and 13 of KRAS, and the result-
ing PCR products were subjected to cycle sequencing in
reverse reactions.
Genzyme Corporation (Cambridge, MA) used an
allele-specific primer extension technique and reported
results for any mutation of codons 12 and 13.
Invitek GmbH (Berlin, Germany) used their Invisorb®
Spin Tissue Mini Kit for DNA extraction and evaluated
KRAS mutational status using their Invigene® K-ras Geno-
typing Kit, which employs allele-specific oligonucleotide
hybridization. Results were reported for 6 possible muta-
tions at each of codons 12 and 13.
Agencourt Bioscience Corporation conducted picoti-
ter plate pyrosequencing using the Roche 454 system
described previously [7-9]. Briefly, unique barcode-con-
taining primers were used to amplify KRAS exon 2. All
the uniquely tagged samples were pooled at equimolar
concentrations and adaptors were ligated to allow bead
binding. Optimized mixing conditions were then used to
ensure that each bead-bound DNA molecule was within
an oil droplet that contained PCR reagents. Emulsion
PCR was performed using primers that included biotin to
enable selective capture of those beads where successful
amplification took place. The emulsion was subsequently
broken, the biotin-containing beads captured, and each
bead loaded by centrifugation into 1 well of a picotiter
plate. Traditional pyrosequencing was performed, yield-
ing a library of sequences linked to unique barcodes.
Results were reported as the sequences derived from
flowgrams, together with the 10-bp sequences employed
for each sample to allow deconvolution of the data at
Amgen. The number of mutant and wild-type sequences
for each sample was reported.
Statistical Analysis
KRAS  genotype was classified as either wild type or
mutant. Techniques were considered to be in agreement
if both identified wild type or a mutant, even if the allele
reported was different. Agreement was assessed by κ sta-
tistics [10] using SAS/STAT® software version 9.1 (SAS
Institute, Cary, NC).
Table 1: Patient Demographics and Tumor Characteristics
All Patients (N = 40)
Sex, n (%)
Men 14 (35)
Women 20 (50)
Missing 6 (15)
Median age,* yrs (range) 67 (35-94)
Primary diagnosis, n (%)
Colon adenocarcinoma 36 (90)
Rectal adenocarcinoma 3 (7.5)
Rectal carcinoma 1 (2.5)
*Age data were not available for 7 patients.Oliner et al. Diagnostic Pathology 2010, 5:23
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Results
Results of Direct Sequencing by the Amgen DNA 
Sequencing Laboratory
Twenty (50%) patients had KRAS exon 2 mutations in
sequencing performed by Amgen: G13D (n = 10), G12D
(n = 5), G12V (n = 5), G12A (n = 2), and G12S (n = 1)
(Table 2). Three of the G13D mutations occurred in com-
bination with a codon 12 mutation.
Comparability of KRAS Mutational Analysis
Variation was observed in the comparability of direct
sequencing by Amgen and the results of commercial
analyses as shown by the tabulation of the reported
results (Table 2) and the comparison of these results
using the κ statistic (Table 3). The results of allele-specific
testing by HistoGeneX using the DxS kit (κ = 0.95; 95%
CI, 0.83—1.00) and by Genzyme (κ = 0.94; 95% CI,
0.85—1.00) closely matched the results of direct sequenc-
ing by Amgen, differing on 2/40 samples and 1/35 sam-
ples, respectively. The results of picotiter plate
s e q u e n c i n g  b y  A g e n c o u r t  w e r e  a l s o  a l m o s t  i n  p e r f e c t
agreement with the results of direct sequencing by
Amgen (κ = 0.94; 95% CI 0.52—0.98; 32 results reported
from 35 samples). Results from the 2 techniques differed
in only 1 sample when making a determination of KRAS
wild-type versus mutant sequence. Amgen direct
sequencing identified sample 9 as wild type, whereas
Agencourt picotiter plate sequencing detected a G12V
mutation. The results of direct sequencing by Gentris
were in substantial agreement with the results of direct
sequencing by Amgen, with disagreement on 4 samples
(κ = 0.75; 95% CI, 0.52—0.98; 32 results reported from 40
samples). The results of mutational analysis by allele-spe-
cific oligonucleotide hybridization by Invitek (as con-
ducted in 2007) were in slight agreement with the results
of direct sequencing by Amgen (κ = 0.13; 95% CI
0.15—0.42; 27 results reported from 40 samples). KRAS
analysis by Invitek identified only 3 wild-type samples, 2
of which were in agreement with direct sequencing by
Amgen.
The quantitative nature of the Agencourt picotiter plate
sequencing assay, which generates counts of mutant and
wild-type sequences, provided additional data that, in
many instances, allowed clarification of the results from
other laboratories (Table 2). For example, 3 of the 5 other
laboratories detected the G12S mutation in sample 7,
whereas picotiter plate sequencing identified the mutant
allele in 6% of the DNA. In sample 21, direct sequencing
by Amgen identified a G13D mutation, HistoGeneX
detected a G12D mutation, and Invitek and Genzyme
detected both G13D and G12D mutants. Picotiter plate
sequencing identified G13D and G12D mutations in 26%
and 12% of the DNA, respectively. In sample 9, picotiter
plate sequencing identified a G12V mutation in 41% of
sample DNA, whereas the other assays identified a wild-
type genotype. It is unclear whether this is due to tumor
heterogeneity or other factors.
Discussion
The results of this study suggest that analyses of KRAS
mutational status by most commercial services are accu-
rate and are generally in close agreement with results of
direct sequencing by Amgen. The results from Agen-
court, HistoGeneX/DxS, and Genzyme were in almost
perfect agreement with Amgen sequencing data and the
results from Gentris were in substantial agreement with
the Amgen analysis, whereas the results from Invitek
were in slight agreement. It should be noted that Invitek
has released a new assay since these comparisons were
performed in 2007. The allele-specific oligonucleotide
hybridization assay used in this study is no longer com-
mercially available and has been replaced by an alterna-
tive technique. The frequency of KRAS mutation (20/40
as assessed by the Amgen laboratory) in the tumor biopsy
specimens used in this study is consistent with that previ-
ously observed in clinical studies investigating KRAS
mutations in CRC [11,12]. In 2007, these data (together
with other considerations) led to the selection of the DxS
assay performed by HistoGeneX for the evaluation of
KRAS  mutational status in samples from the panitu-
mumab pivotal trial [4].
Several factors may have contributed to the lack of
agreement between KRAS testing assays observed in this
study. These factors may have included differences in the
sensitivity and specificity of KRAS tests, differences in
sample processing and DNA enrichment techniques
between laboratories, and variation in tumor content
between tumor samples and within tumor samples.
Although direct sequencing is typically considered the
gold standard for mutational analysis, emulsion PCR fol-
lowed by picotiter plate sequencing may offer several
advantages [13]. Because of the high sensitivity of picoti-
ter plate sequencing, accurate detection of very low abun-
dance mutations in a tumor sample is feasible [7]. Indeed,
this highlights an important issue regarding sample selec-
tion for concordance studies of somatic mutation analysis
in solid tumor specimens. Ideally, samples for concor-
dance studies would comprise serial sections from a sin-
gle homogeneous tumor block, allowing both
preanalytical and analytical variables to be measured as a
composite from a single sample. However, serial sections
from a single block distributed amongst analytical plat-
forms is not ideal given the likelihood of variable ratios of
tumor:normal:stromal:necrotic tissue among sections
and the potential for tumor heterogeneity (as suggested
by results for samples 8 and 21, which contained 2 differ-
ent mutations that might vary in ratio through the block).
We propose that concordance testing should be a 2-stepOliner et al. Diagnostic Pathology 2010, 5:23
http://www.diagnosticpathology.org/content/5/1/23
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Table 2: KRAS Mutations Reported by Mutation Analysis Method
Sample Direct 
Sequencing 
(Amgen)
Allele-
Specific PCR 
(HistoGeneX
/DxS)
Direct 
Sequencing 
(Gentris)
Allele-Specific 
Hybridization 
(Invitek)
Allele-
Specific PCR 
Extensions 
(Genzyme)
Picotiter Plate 
Sequencing 
(Agencourt)*
Samples for 
which a KRAS 
sequence 
determination 
was made, n
40 40 32 27 35 32
Total WT, n 20 21 18 3 15 15
1 G13D G13D G13D G13D G13D G13D (4219/7836; 
0.54)**
2W T W T W T I n c o n c l u s i v e † WT WT (8880)**
3 G13D G13D 12WT, no call 
13†
G13D G13D G13D (1679/8282; 
0.2)
4W T W T W T I n c o n c l u s i v e † WT WT (8371)
5 WT WT WT G13D WT Not tested
6 G12A G12A G12A WT G12A No result†
7 G12S, G13D G12S G12S, no call 
13†
Inconclusive† Failed† G12S (53/825; 
0.06)
8 G12V, G13D G12V G12V G12S, G12V G12V G12V (244/1289; 
0.19), G13D (53/
1289; 0.04)
9 WT WT WT Not analyzed‡ Failed† G12V (43/106; 
0.41)
10 WT WT 12WT, no call 
13†
WT Failed† WT (18)
11 WT WT Mixed 
sequence§
Not analyzed‡ Failed† No result†
12 G12V G12V G12V G12D, G13D G12V G12V (2443/4707; 
0.52)
13 WT WT WT G13D WT WT (9223)
14 WT WT WT Inconclusive† WT WT (9921)
15 G12D G12D G12D G12D, G13D G12D G12D (4178/8006; 
0.52)
16 WT WT WT Inconclusive† WT WT (7001)
17 G13D G13D No call 12 or 
13†
G13D G13D Not tested||
18 G12A G12A G12A G12A, G13D G12A Not tested||
19 WT WT WT G13D WT WT (8891)
20 G12D G12D G12D G12D G12D G12D (2513/4304; 
0.58)
21 G13D G12D WT G12D, G13D G12D, G13D G12D (761/6260; 
0.12), G13D (1639/
6260; 0.26)
22 WT WT WT Inconclusive† WT WT (2908)
23 G12D G12D WT Inconclusive† G12D G12D (2115/7262; 
0.29)
24 WT WT No 
amplification¶
WT Failed† WT (71)Oliner et al. Diagnostic Pathology 2010, 5:23
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process using separate sets of samples. The first would
determine the ability to successfully extract PCR-amplifi-
able DNA (by employing sections from a range of tumor
blocks with variable tumor:normal:stromal:necrotic tis-
sue ratios) with a second set of samples (comprising ali-
quots from DNA extracts with predetermined
mutant:wild-type somatic mutation ratios) to determine
the ability to correctly report mutations. Some of these
samples should be close to the lower level of sensitivity
expected of such assays (eg., 1%).
KRAS  mutation assays may provide physicians with
guidance when making decisions on the use of anti-EGFR
therapy in the treatment of metastatic CRC [14]. How-
ever, the lack of concordance among results of some assay
techniques emphasizes the importance of a rigorous
quality assurance program to ensure that results are of
high quality [15-17], potentially using the sample types
described above.
Whitehall et al recently published a study comparing 6
KRAS mutation assays in the analysis of primary colorec-
tal cancer samples [18]. As in this study, most techniques
assessed were found to be in good agreement, with some
notable exceptions. The key strength of our study was
that laboratories (with the exception of Agencourt) ana-
lyzed KRAS from tumor sections on glass slides rather
t h a n  f r o m  D N A ,  a n d  t h e  r e s u l t s  w e r e  c o n s e q u e n t l y  a
closer mimic of clinical testing procedures. A recent
s t u d y  b y  W e i c h e r t  e t  a l  c o m p a r e d  4  KRAS  mutation
assays of primary colorectal cancer samples and metasta-
ses using DNA extracted from tumor sections on glass
slides and similarly determined that the assay techniques
were generally in good agreement [19].
Conclusions
The results of this study suggest that most (but not all)
commercial services provide analysis that is accurate and
25 WT WT WT G13D WT WT (2477)
26 WT WT WT Inconclusive† WT WT (5887)
27 G12V G12V G12V G12V G12V G12V (1812/6404; 
0.28)
28 WT WT WT Inconclusive† WT WT (8696)
29 WT WT G12V G13D WT WT (3876)
30 G13D G13D G13D G13D G13D G13D (4697/9754; 
0.48)
31 WT WT No 
amplification
G12D, G13D G13D No result†
32 WT WT WT G13D WT WT (5048)
33 G12V G12V WT G12V, G13D G12V G12V (505/1042; 
0.48)
34 WT WT WT G13D WT WT (6329)
35 G13D G13D G13D G13D G13D G13D (2578/7158; 
0.36)
36 G12V, G13D G12V G12V Inconclusive† G12V Not tested||
37 G12D G12D G12D G12D, G13D G12D G12D (14/61; 0.23)
38 G13D WT 12WT, no call 
13†
G13D G13D G13D (1539/5423; 
0.28)
39 WT WT WT G13D WT Not tested||
40 G12D G12D G12D Inconclusive† G12D G12D (1884/4565; 
0.41)
PCR = polymerase chain reaction; WT = wild type.
*Numbers in parentheses indicate the proportion of sample DNA containing the mutant allele.
†Service was unable to conclusively determine genotype.
‡Sample was determined to be unsuitable for subsequent hybridization.
§Multiple observed sequences precluded deconvolution of sequence traces.
||Samples no longer available for testing.
¶KRAS sequence could not be amplified by PCR.
**The single number in parentheses refers to the total sequence reads for that sample when all were WT, and for MT, the fraction reflects the 
number of sequence reads for a given mutation over the total number of sequence reads for that sample, followed by the numerical fraction 
of that ratio.
Table 2: KRAS Mutations Reported by Mutation Analysis Method (Continued)Oliner et al. Diagnostic Pathology 2010, 5:23
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comparable with direct sequencing. However, the lack of
concordance among results of some assay techniques,
suggest that rigorous quality assurance programs will be
necessary to ensure consistent and accurate results.
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